InvestorPlace - Stock Market News, Stock Advice & Trading Tips Mornings like we had on Wednesday are exactly why I get up and ...

Piper Sandler analyst Allison Bratzel maintained a Hold rating on Humacyte today and set a price target of $1.00. Unlock powerful investing tools and data-driven insights with TipRanks Premium for ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of ...

AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus ...

Travere Therapeutics said Chief Research Officer William Rote plans to retire from the company in February. Chief Medical Officer Julia Inrig will expand her responsibilities to include the company's ...

Fresh off a deal with Travere Therapeutics Inc. for civorebrutinib worth more than $1.14 billion, Everest Medicines Ltd. went on a shopping spree, striking three deals in six days to expand its ...

Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on Biotech Distilled’s Substack.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on June 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026.

HealthInvest showcased ASX-listed healthcare companies where scientific innovation, commercial opportunity and patient outcomes align.